Advanced search
Add to list

Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies

Liv Veldeman (UGent) , Indira Madani (UGent) , Frank Hulstaert, Gert De Meerleer (UGent) , Marcus Mareel (UGent) and Wilfried De Neve (UGent)
(2008) LANCET ONCOLOGY. 9(4). p.367-375
Author
Organization
Abstract
Since its introduction more than a decade ago, intensity-modulated radiotherapy (IMRT) has spread to most radiotherapy departments worldwide for a wide range of indications. The technique has been rapidly implemented, despite an incomplete understanding of its advantages and weaknesses, the challenges of IMRT planning, delivery, and quality assurance, and the substantially increased cost compared with non-IMRT Many publications discuss the theoretical advantages of IMRT dose distributions. However, the key question is whether the use of IMRT can be exploited to obtain a clinically relevant advantage over non-modulated external-beam radiation techniques. To investigate which level of evidence supports the routine use of IMRT for various disease sites, we did a review of clinical studies that reported on overall survival, disease-specific survival, quality of life, treatment-induced toxicity, or surrogate endpoints. This review shows evidence of reduced toxicity for various tumour sites by use of IMRT The findings regarding local control and overall survival are generally inconclusive.

Citation

Please use this url to cite or link to this publication:

MLA
Veldeman, Liv, Indira Madani, Frank Hulstaert, et al. “Evidence Behind Use of Intensity-modulated Radiotherapy: a Systematic Review of Comparative Clinical Studies.” LANCET ONCOLOGY 9.4 (2008): 367–375. Print.
APA
Veldeman, L., Madani, I., Hulstaert, F., De Meerleer, G., Mareel, M., & De Neve, W. (2008). Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. LANCET ONCOLOGY, 9(4), 367–375.
Chicago author-date
Veldeman, Liv, Indira Madani, Frank Hulstaert, Gert De Meerleer, Marcus Mareel, and Wilfried De Neve. 2008. “Evidence Behind Use of Intensity-modulated Radiotherapy: a Systematic Review of Comparative Clinical Studies.” Lancet Oncology 9 (4): 367–375.
Chicago author-date (all authors)
Veldeman, Liv, Indira Madani, Frank Hulstaert, Gert De Meerleer, Marcus Mareel, and Wilfried De Neve. 2008. “Evidence Behind Use of Intensity-modulated Radiotherapy: a Systematic Review of Comparative Clinical Studies.” Lancet Oncology 9 (4): 367–375.
Vancouver
1.
Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. LANCET ONCOLOGY. 2008;9(4):367–75.
IEEE
[1]
L. Veldeman, I. Madani, F. Hulstaert, G. De Meerleer, M. Mareel, and W. De Neve, “Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies,” LANCET ONCOLOGY, vol. 9, no. 4, pp. 367–375, 2008.
@article{505544,
  abstract     = {Since its introduction more than a decade ago, intensity-modulated radiotherapy (IMRT) has spread to most radiotherapy departments worldwide for a wide range of indications. The technique has been rapidly implemented, despite an incomplete understanding of its advantages and weaknesses, the challenges of IMRT planning, delivery, and quality assurance, and the substantially increased cost compared with non-IMRT Many publications discuss the theoretical advantages of IMRT dose distributions. However, the key question is whether the use of IMRT can be exploited to obtain a clinically relevant advantage over non-modulated external-beam radiation techniques. To investigate which level of evidence supports the routine use of IMRT for various disease sites, we did a review of clinical studies that reported on overall survival, disease-specific survival, quality of life, treatment-induced toxicity, or surrogate endpoints. This review shows evidence of reduced toxicity for various tumour sites by use of IMRT The findings regarding local control and overall survival are generally inconclusive.},
  author       = {Veldeman, Liv and Madani, Indira and Hulstaert, Frank and De Meerleer, Gert and Mareel, Marcus and De Neve, Wilfried},
  issn         = {1470-2045},
  journal      = {LANCET ONCOLOGY},
  language     = {eng},
  number       = {4},
  pages        = {367--375},
  title        = {Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies},
  volume       = {9},
  year         = {2008},
}

Web of Science
Times cited: